Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases |
| |
| Affiliation: | 1. Neurotoxicology Research Group, Toxicology Division, Institute for Risk Assessment Sciences (IRAS), Faculty of Veterinary Medicine, Utrecht University, P.O. Box 80177 NL-3508 TD Utrecht, The Netherlands;2. Drug Monitoring, Netherlands Institute of Mental Health and Addiction, P.O. Box 725, NL-3500 AS Utrecht, The Netherlands;3. General Recreational Drug Consulting Hours, Brijder Addiction Care Center, Richard Holkade 4, NL-2033 PZ Haarlem, The Netherlands;1. Neuropsychopharmacology Research Group, School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland;2. Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Ireland;3. Neuroimmunology Research Group, Department of Physiology, School of Medicine, Trinity College, Dublin 2, Ireland;1. Section of Pharmaceutical Technology, Department of Drug Sciences, University of Catania, Catania, Italy;2. Section of Pharmacology and Biochemistry, Department of Clinical and Molecular Biomedicine, School of Medicine, University of Catania, Catania, Italy;3. NANO-i, Research Centre on Ocular Nanotechnology, University of Catania, Catania, Italy;1. Department of Zoology, University of Oxford, OX1 3PS, UK;2. Department of Experimental Psychology, University of Oxford, OX2 6GG, UK;1. Department of Pharmacology, University of Oxford, Mansfield Road, OX1 3QT, UK;2. Forensic Adviser, Advisory Council on the Misuse of Drugs (ACMD) Secretariat, 2 Marsham Street, London SW1P 4DP, UK;3. LGC Forensics, Queens Road, Teddington, London TW11 0LY, UK |
| |
| Abstract: | ![]()
Hallucinogen persisting perception disorder (HPPD) is a drug-induced condition associated with inaccurate visual representations. Since the underlying mechanism(s) are largely unknown, this review aims to uncover aspects underlying its etiology. Available evidence on HPPD and drug-related altered visual processing was reviewed and the majority of HPPD cases were attributed to drugs with agonistic effects on serotonergic 5-HT2A receptors. Moreover, we present 31 new HPPD cases that link HPPD to the use of ecstasy (MDMA), which is known to reverse serotonin reuptake and acts as agonist on 5-HT2A receptors. The available evidence suggests that HPPD symptoms may be a result from a misbalance of inhibitory-excitatory activity in low-level visual processing and GABA-releasing inhibitory interneurons may be involved. However, high co-morbidities with anxiety, attention problems and derealization symptoms add complexity to the etiology of HPPD. Also, other perceptual disorders that show similarity to HPPD cannot be ruled out in presentations to clinical treatment. Taken together, evidence is still sparse, though low-level visual processing may play an important role. A novel finding of this review study, evidenced by our new cases, is that ecstasy (MDMA) use may also induce symptoms of HPPD. |
| |
| Keywords: | HPPD Hallucinogen LSD MDMA Ecstasy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
